Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regeneron Lays Out Commercial Case For Arcalyst In Gout Flares To Investors; Convincing Payers May Be Challenge

This article was originally published in The Pink Sheet Daily

Executive Summary

During the biopharma's first ever investor day, management outlines early plans for the launch of Arcalyst for the prevention of gout flares.
Advertisement

Related Content

Regeneron Eyes Another Pipeline Target: Arcalyst In Gout
Regeneron Eyes Another Pipeline Target: Arcalyst In Gout
Ready To Launch But Nowhere To Go: Regeneron's Eylea Gets FDA Delay
Ready To Launch But Nowhere To Go: Regeneron's Eylea Gets FDA Delay
Regeneron/Bayer Bullish On Wet-AMD Drug But Commercial Success Is No Guarantee
Regeneron/Bayer Bullish On Wet-AMD Drug But Commercial Success Is No Guarantee
As Gout Market Opens Up, Experts Await Therapies To Better Lower Uric Acid
As Gout Market Opens Up, Experts Await Therapies To Better Lower Uric Acid

Topics

Advertisement
UsernamePublicRestriction

Register

PS070903

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel